{
}
UBS has downgraded Novartis from "Buy" to "Neutral," significantly lowering its price target from 111 to 104 Swiss francs. Analyst Matthew Weston highlighted the company's challenges, including numerous patent expiries and a lack of promising developments in the research pipeline, predicting underperformance through 2025. Novartis shares fell by 1.35% to CHF 96.48 following the announcement.
UBS has downgraded Novartis from "Buy" to "Neutral," reducing its price target from 111 to 104 Swiss francs. Analyst Matthew Weston highlighted the company's upcoming patent expiries and a lack of promising developments in its research pipeline, favoring AstraZeneca as a buy instead.
UBS has downgraded Novartis from "Buy" to "Neutral," reducing its price target from 111 to 104 Swiss francs. Analyst Matthew Weston highlighted the company's upcoming patent expiries and a lack of significant new developments in the research pipeline for 2025, favoring AstraZeneca as a buy instead.
UBS has upgraded AstraZeneca from "Neutral" to "Buy," raising its price target from 11,500 to 14,200 pence. Analyst Matthew Weston highlighted the company's significant pipeline potential, projecting an additional USD 17.6 billion in sales by 2030, contingent on successful trial outcomes for seven key drugs in 2025.
UBS has downgraded Novartis from "Buy" to "Neutral," reducing its price target from 111 to 104 Swiss francs. Analyst Matthew Weston highlighted the company's upcoming patent expiries and a lack of promising developments in its research pipeline for 2025, favoring AstraZeneca as a buy instead.
UBS has downgraded Novartis from "Buy" to "Neutral," reducing its price target from 111 to 104 Swiss francs. Analyst Matthew Weston highlighted the company's upcoming patent expiries and a lack of significant new developments in its research pipeline for 2025, favoring AstraZeneca as a better investment option.
UBS has upgraded AstraZeneca from "Neutral" to "Buy," raising the price target from 11,500 to 14,200 pence. Analyst Matthew Weston highlighted the company's significant pipeline potential, estimating an additional $17.6 billion in revenue by 2030 if late-stage candidates succeed, with 2025 being pivotal for seven key drug results.
UBS has upgraded AstraZeneca from "Neutral" to "Buy," raising its price target from 11,500 to 14,200 pence. Analyst Matthew Weston highlighted the company's strong pipeline, predicting an additional $17.6 billion in sales by 2030, with 2025 being crucial for the results of seven key drug trials.
UBS has downgraded Novartis from Buy to Neutral, lowering the price target from CHF111 to CHF104, citing concerns over upcoming patent expirations that could slow growth. Despite a strong product portfolio and solid financial health, the company faces challenges that may impact its market performance by mid-2025. Additionally, Novartis is nearing EU antitrust approval for its $16.5 billion acquisition of Catalent, which could enhance its manufacturing capabilities.
UBS has upgraded AstraZeneca's stock rating from Neutral to Buy, raising the price target to GBP142.00 from GBP115.00, citing strong fundamentals and a robust late-stage pipeline. The company is projected to achieve a 6% revenue CAGR through 2030, with significant drug approvals expected in 2025. Other firms, including BofA Securities and Morgan Stanley, also maintain positive ratings, reflecting confidence in AstraZeneca's growth potential and product development.
Matthew Weston
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Novartis shares decline as UBS downgrades rating and price target
10:28 13.02.2025
UBS downgrades Novartis to neutral amid patent expiry concerns
09:05 13.02.2025
ubs downgrades novartis to neutral lowers price target to 104 francs
08:05 13.02.2025
UBS upgrades AstraZeneca to buy with target raised to 14200 pence
08:05 13.02.2025
ubs downgrades novartis to neutral lowers price target to 104 francs
08:05 13.02.2025
UBS downgrades Novartis to neutral amid patent expiries and weak pipeline
Swiss Franc
Novartis AG
AstraZeneca PLC
CHE
Warren Buffett
Matthew Weston
Hubert Dichtl
Thomas Müller
Show more
07:46 13.02.2025
ubs upgrades astrazeneca to buy raises price target significantly
07:46 13.02.2025
UBS upgrades AstraZeneca to buy citing strong sales potential through 2030
07:30 13.02.2025
ubs downgrades novartis stock rating and lowers price target amid challenges
07:22 13.02.2025
ubs upgrades astrazeneca to buy with increased price target and positive outlook
07:13 13.02.2025
Trending
Subcategory
Corporate News
Industry Trends
Stock Market Updates
Retail and Consumer Goods
Global Financial Events
Finance Mergers & Acquisitions
Global Trade Developments
Industry Mergers & Acquisitions
Central Bank Actions
CEO Changes
Banking Regulations
Supply Chain Management
Startups & Entrepreneurship
Energy Sector Developments
Government Economic Policies
Workplace Trends
AI Innovations
Cryptocurrency Trends
Market Analysis and Predictions
Financial Scams and Security
Countries:
Companies:
The Goldman Sachs Group, Inc.
Bank of America Corporation
Apple Inc.
Alphabet Inc.
Barclays PLC
Tesla, Inc.
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank RV Global PP
Commerzbank AG
Lloyds Banking Group plc
PepsiCo, Inc.
BNP Paribas SA
Google Inc.
NVIDIA Corporation
UBS Group AG
Wix.com Ltd.
BP Castrol K.K.
Valvoline Inc.
Bosch Limited
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Indian Rupee
Japanese Yen
Indonesian Rupiah
Canadian Dollar
Russian Ruble
South Korean Won
United Arab Emirates Dirham
Offshore Chinese Yuan
Ghanaian Cedi
Hungarian Forint
Albanian Lek
Brazilian Real
Singapore Dollar
Qatari Riyal
Jordanian Dinar
People:
Donald Trump
Elon Musk
Warren Buffett
Sergey Brin
Larry Page
Goldman Sachs
Kelvin Taylor
Carsten Fritsch
Christopher Chandler
Scott Bessent
Martin Schlegel
Jerome Powell
Kubra Khan
Joe Biden
Volkmar Baur
Christopher Wallerstedt
Brian Moynihan
Airlangga Hartarto
Francesco Gaetano Caltagirone
Leonardo Del Vecchio